135 related articles for article (PubMed ID: 35511670)
1. Pure erythroid leukemia is characterized by biallelic
Fang H; Wang SA; Khoury JD; El Hussein S; Kim DH; Tashakori M; Tang Z; Li S; Hu Z; Jelloul FZ; Patel KP; McDonnell TJ; Kadia T; Medeiros LJ; Wang W
Haematologica; 2022 Sep; 107(9):2232-2237. PubMed ID: 35511670
[No Abstract] [Full Text] [Related]
2. Differential characteristics of TP53 alterations in pure erythroid leukemia arising after exposure to cytotoxic therapy.
Tashakori M; Wang W; Kadia TM; Daver NG; Montalban-Bravo G; Loghavi S; Wang SA; Medeiros LJ; Ravandi F; Khoury JD
Leuk Res; 2022 Jul; 118():106860. PubMed ID: 35636055
[TBL] [Abstract][Full Text] [Related]
3. MDM4 overexpressed in acute myeloid leukemia patients with complex karyotype and wild-type TP53.
Li L; Tan Y; Chen X; Xu Z; Yang S; Ren F; Guo H; Wang X; Chen Y; Li G; Wang H
PLoS One; 2014; 9(11):e113088. PubMed ID: 25405759
[TBL] [Abstract][Full Text] [Related]
4. TP53 deleted cells in de novo glioblastomas using fluorescence in situ hybridization.
Horiguchi H; Sano T; Hirose T
Pathol Int; 2001 Mar; 51(3):187-92. PubMed ID: 11328534
[TBL] [Abstract][Full Text] [Related]
5. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia.
Kurotaki H; Tsushima Y; Nagai K; Yagihashi S
Acta Haematol; 2000; 102(3):115-23. PubMed ID: 10692673
[TBL] [Abstract][Full Text] [Related]
6. PRIMA-1
Jaskova Z; Pavlova S; Malcikova J; Brychtova Y; Trbusek M
Leuk Res; 2020 Feb; 89():106288. PubMed ID: 31924585
[TBL] [Abstract][Full Text] [Related]
7. TP53 mutation characteristics in therapy-related myelodysplastic syndromes and acute myeloid leukemia is similar to de novo diseases.
Ok CY; Patel KP; Garcia-Manero G; Routbort MJ; Peng J; Tang G; Goswami M; Young KH; Singh R; Medeiros LJ; Kantarjian HM; Luthra R; Wang SA
J Hematol Oncol; 2015 May; 8():45. PubMed ID: 25952993
[TBL] [Abstract][Full Text] [Related]
8. More than 1
Montalban-Bravo G; Benton CB; Wang SA; Ravandi F; Kadia T; Cortes J; Daver N; Takahashi K; DiNardo C; Jabbour E; Borthakur G; Konopleva M; Pierce S; Bueso-Ramos C; Patel K; Kornblau S; Kantarjian H; Young KH; Garcia-Manero G; Andreeff M
Blood; 2017 May; 129(18):2584-2587. PubMed ID: 28246192
[No Abstract] [Full Text] [Related]
9. The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications.
Zhang L; McGraw KL; Sallman DA; List AF
Leuk Lymphoma; 2017 Aug; 58(8):1777-1790. PubMed ID: 27967292
[TBL] [Abstract][Full Text] [Related]
10.
George B; Kantarjian H; Baran N; Krocker JD; Rios A
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639121
[TBL] [Abstract][Full Text] [Related]
11. p53 pathway dysfunction is highly prevalent in acute myeloid leukemia independent of TP53 mutational status.
Quintás-Cardama A; Hu C; Qutub A; Qiu YH; Zhang X; Post SM; Zhang N; Coombes K; Kornblau SM
Leukemia; 2017 Jun; 31(6):1296-1305. PubMed ID: 27885271
[TBL] [Abstract][Full Text] [Related]
12. p53 dysfunction in B-cell chronic lymphocytic leukemia: inactivation of ATM as an alternative to TP53 mutation.
Pettitt AR; Sherrington PD; Stewart G; Cawley JC; Taylor AM; Stankovic T
Blood; 2001 Aug; 98(3):814-22. PubMed ID: 11468183
[TBL] [Abstract][Full Text] [Related]
13. Identification of molecular and functional patterns of p53 alterations in chronic lymphocytic leukemia patients in different phases of the disease.
Marinelli M; Peragine N; Di Maio V; Chiaretti S; De Propris MS; Raponi S; Tavolaro S; Mauro FR; Del Giudice I; Guarini A; Foà R
Haematologica; 2013 Mar; 98(3):371-5. PubMed ID: 22983585
[TBL] [Abstract][Full Text] [Related]
14. Patterns of mutations in TP53 mutated AML.
Welch JS
Best Pract Res Clin Haematol; 2018 Dec; 31(4):379-383. PubMed ID: 30466751
[TBL] [Abstract][Full Text] [Related]
15. Reassessment of p53 immunohistochemistry thresholds in invasive high grade bladder cancer shows a better correlation with TP53 and FGFR3 mutations.
Hodgson A; van Rhijn BWG; Kim SS; Ding C; Saleeb R; Vesprini D; Liu SK; Yousef GM; van der Kwast TH; Xu B; Downes MR
Pathol Res Pract; 2020 Nov; 216(11):153186. PubMed ID: 32861170
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of p53 Functional De-Regulation: Role of the IκB-α/p53 Complex.
Carrà G; Crivellaro S; Taulli R; Guerrasio A; Saglio G; Morotti A
Int J Mol Sci; 2016 Nov; 17(12):. PubMed ID: 27916821
[No Abstract] [Full Text] [Related]
17. TP53 mutations in de novo acute myeloid leukemia patients: longitudinal follow-ups show the mutation is stable during disease evolution.
Hou HA; Chou WC; Kuo YY; Liu CY; Lin LI; Tseng MH; Chiang YC; Liu MC; Liu CW; Tang JL; Yao M; Li CC; Huang SY; Ko BS; Hsu SC; Chen CY; Lin CT; Wu SJ; Tsay W; Chen YC; Tien HF
Blood Cancer J; 2015 Jul; 5(7):e331. PubMed ID: 26230955
[TBL] [Abstract][Full Text] [Related]
18. Constant p53 pathway inactivation in a large series of soft tissue sarcomas with complex genetics.
Pérot G; Chibon F; Montero A; Lagarde P; de Thé H; Terrier P; Guillou L; Ranchère D; Coindre JM; Aurias A
Am J Pathol; 2010 Oct; 177(4):2080-90. PubMed ID: 20884963
[TBL] [Abstract][Full Text] [Related]
19. Age-dependent copy number variations of TP53 tumour suppressor gene associated with altered phosphorylation status of p53 protein in sporadic schwannomas.
Chen H; Huang H; Zhao J; Wang Z; Chang M; Xue L; Zhu W; Chai Y; Li G; Wang Z; Wu H
J Neurooncol; 2019 Jul; 143(3):369-379. PubMed ID: 31049827
[TBL] [Abstract][Full Text] [Related]
20. Acute lymphoblastic leukemia with low hypodiploid/near triploid karyotype is a specific clinical entity and exhibits a very high TP53 mutation frequency of 93%.
Mühlbacher V; Zenger M; Schnittger S; Weissmann S; Kunze F; Kohlmann A; Bellos F; Kern W; Haferlach T; Haferlach C
Genes Chromosomes Cancer; 2014 Jun; 53(6):524-36. PubMed ID: 24619868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
